Exegenesis Bio Completes Series B++ Financing; Raises $120 M to Date

PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release

Scroll to top